PROCYON CORPORATION

PCYN ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018 FY2017
Operating Activities
Net Income $-341.1K $-50.2K $-209.8K $694.3K $111.7K $27.2K $-255.7K $12.4K
Depreciation & Amortization
Depreciation $81.7K $52.8K $38.2K $43.3K $53.9K $52.6K $47.9K $45.7K
Amortization
Stock-Based Compensation $0 $0 $19.7K $4.7K
Net Cash from Operating Activities $-61.3K $145.5K $-383.5K $279.5K $198.8K $50.8K $86.5K $199.6K
Investing Activities
Capital Expenditures $63.9K $180.1K $82.6K $65.2K $23.0K $28.8K $46.7K $18.9K
Business Acquisitions
Net Cash from Investing Activities $-63.9K $-454.6K $-82.6K $480.1K $-24.2K $-28.8K $14.4K $43.2K
Financing Activities
Dividends Paid
Stock Repurchases
Net Cash from Financing Activities $0 $0 $0 $-198.9K $201.0K $-2.1K $-3.8K $-128.8K
Net Change in Cash $-125.2K $-309.1K $-466.1K $560.7K $375.5K $20.0K $97.1K $114.0K
Free Cash Flow $-125.2K $-34.7K $-466.1K $214.3K $175.7K $22.1K $39.8K $180.7K
← Newer Page 1 of 2 Older →